proscript การใช้

• So ProScript, as MyoGenics was renamed, began trying the drug in various cancers.
• With just weeks of cash left, prospects for ProScript Inc . and PS-341 looked dim.
• ProScript's proposed drug, called PS-341, is a new class of antitumor chemotherapeutic agents.
• Lactacystin was licensed to Myogenics / Proscript, which was acquired by Millennium Pharmaceuticals, now part of Takeda Pharmaceuticals.
• Then LeukoSite Inc ., a Cambridge biotechnology company, bought ProScript for $ 2.4 million, granting the drug a last-minute reprieve.
• Part of its drug pipeline comes from a pair of Cambridge biotech companies _ ProScript Inc . and CytoMed Inc . _ that LeukoSite acquired earlier this year.
• LeukoSite, also initially funded by Healthcare Ventures, acquired ProScript which in turn was acquired by Millenium Pharmaceuticals, the company that successfully brought Velcade to market.
• ProScript, formerly MyoGenics, has developed a new way of regulating inflammatory response and cell division for use in AIDS-related illnesses, inflammation disorders and cancer.
• Among these was ProScript Inc . ProScript discovered Velcade, an inhibitor of the proteosome, that has proved to be an effective treatment for multiple myeloma and other cancers.
• Among these was ProScript Inc . ProScript discovered Velcade, an inhibitor of the proteosome, that has proved to be an effective treatment for multiple myeloma and other cancers.
• ""'Secret Service " "'was a Polish monthly magazine for gaming and consoles published from 1993-2001 by the publishing house ProScript.
• "We believe that this acquisition offers significant scientific and business synergies for the future, " said Dan Burns, president of ProScript, who is leaving the company.
• But with many doubting the drug would work, Proscript ran out of money in 1999 and was sold to LeukoSite, another Cambridge company, for $ 2.4 million.
• ProScript, a 7-year-old company, has struggled in recent years with a spate of top management changes and difficulty raising additional funding for human clinical testing of its drugs.
• Around the same time, however, a group of Israeli researchers discovered that the proteosome contributed to cell division, suggesting to Adams that ProScript's research might have applications in cancer.
• Maniatis is also a pioneer in the biotechnology industry, having cofounded Genetics Institute, Inc . in 1980, ProScript Pharma in 1994, Acceleron Pharma in 2004, and Kallyope Pharma in 2016.
• "Our focus is on additional corporate deals to validate the science and then pursue the public market with an initial public offering, " said Richard Bagley, president of Cambridge-based ProScript Inc.
• Though the role it played in disease was not clear, Adams and a group of other scientists founded a company called ProScript on the theory that a better understanding of its biology could lead to important new drugs.
• "With ProScript, we are getting a group of first-rate scientists along with two late-stage compounds and great drug discovery platform for future drugs all at a bargain price, " said Augustine Lawlor, LeukoSite chief financial officer.
• For LeukoSite, which last week announced positive results from its pivotal 93-patient clinical trial for an injectable drug, called Campath, to treat the most prevalent form of adult leukemia, the ProScript acquisition will enable the company to expand its cancer-fighting drug treatments.